Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Neisseria Stories

2014-03-04 16:14:15

Researchers have come a step closer to understanding how gonorrhea infections are transmitted. When Neisseria gonorrhoeae, the bacteria responsible for gonorrhea, are exposed to seminal plasma, the liquid part of semen containing secretions from the male genital tract, they can more easily move and start to colonize. The research, led by investigators at Northwestern University in Chicago, appears in mBio®, the online open-access journal of the American Society for Microbiology. "Our...

2014-02-26 08:28:23

DORVAL QC, Feb. 26, 2014 /CNW/ - Novartis announced today that Bexsero(®) (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection.(1) Bexsero(®) is the first broad-coverage vaccine to help protect against MenB...

2014-02-24 08:28:29

- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7....

2013-12-26 08:23:12

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 SummaryMeningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these...

2013-12-26 08:23:10

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 SummaryMeningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons...

2013-12-26 08:23:07

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 SummaryMeningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the...

2013-12-09 08:27:23

-- Bexsero* is indicated to help protect individuals from two months through 17 years of age against meningococcal B disease, including infants, children one to four years and adolescents who are at the greatest risk of infection2,3 -- MenB is the most common type of meningitis in Canada4. It is responsible for 80 per cent of meningococcal cases in infants under one year of age, 67 per cent in one to four...

2013-12-09 00:20:38

-- Bexsero* is indicated to help protect individuals from two months through 17 years of age against meningococcal B disease, including infants, children one to four years and adolescents who are at the greatest risk of infection2,3 -- MenB is the most common type of meningitis in Canada4. It is responsible for 80 per cent of meningococcal cases in infants under one year of age, 67 per cent in one to four...

2013-11-25 23:04:40

Reportbuyer.com just published a new market research report: PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022. London (PRWEB) November 25, 2013 PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium...

2013-08-05 12:28:04

HOUSTON, Aug. 5, 2013 /PRNewswire-USNewswire/ -- Meningitis Angels are celebrating the announcement of the U.S. Food and Drug Administration's (FDA) expanded approval of Menveo, a vaccine used to help prevent meningococcal disease caused by four strains (A,C,Y, W-135) of the bacterium Neisseria meningitidis (N. meningitidis). The vaccine is now approved for use in infants and toddlers starting as early as 2 months of age. Meningococcal disease is an aggressive, fast-acting illness...


Latest Neisseria Reference Libraries

72_d0e074525de5bb741daf382f8d62213f
2011-04-25 16:38:12

Neisseria meningitidis is a heterotrophic gram-negative diplococcal bacterium best known for its role in meningitis and other forms of meningococcal disease such as meningococcemia. It is a major cause of morbidity and mortality during childhood in industrialized countries and is responsible for epidemics in Africa and in Asia. In the US there are approximately 2500 to 3500 cases of N. meningitides infections. Children under 5 are at a higher risk as well as people in the sub-Saharan...

More Articles (1 articles) »